Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CGON 35% 12 months CR?

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon May 03, 2024 4:20pm

133 Views

Post# 36022476

RE:RE:RE:RE:CGON 35% 12 months CR?

By then we will also have hit a $5 Billion USD MC like our competitors! Hopefully

Eoganacht wrote: At AUA 2025 Theralase will probably give a similar presentation except that the number of treatments will be 2 or 3 rather than 18 - 24 and the 24 month CRR will be greater than 30% rather than 20% IMHO

enriquesuave wrote:
Nice find! We are killing them in our durable and longer term data data it seems so far! IMHO

Eoganacht wrote: Yes it looks like 34.9% CRR at 12 months. And this is down to 20% CRR at 21 months !

Here is a link to their presentation:

Pivotal Results from BOND-003

The results and swimmers plot are on slide 8.

6 month DOR = 52 out of 97 patients = 54%
12 month DOR = 29 out of 83 patients= 34.9%

21 months DOR = 14 out of 69 patients = 20%

enriquesuave wrote: Looks like they just presented data and from what I understand 29 out of 83 patients have maintained. They treated 105 patients and 75% have achieved a CR at anytime. 22 patients are still pending data at 12 months. So 29 out of 83 so far = 34.9% CR at 12 months. Seems like we are beating them badly. IMHO time will tell . Will we hit $4 USD Billion MC like them when we get BTD?